Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively ...

AI‑driven protein design creates potent anti‑CRISPR inhibitors that block Cas13 activity, offering a new potential tool for safer, more controlled gene editing.

Researchers have unveiled a way to flip genes back on without slicing into the genome, a shift that could make CRISPR far safer and more flexible. Instead of cutting DNA, the new approach scrubs away ...

In the never-ending quest to discover previously unknown CRISPR gene-editing systems, researchers have scoured microbes in everything from hot springs and peat bogs to poo and even yogurt. Now, thanks ...

Picture CRISPR-Cas9, a gene editing technology, as a GPS-guided scalpel: gRNA directs the Cas9 enzyme, a protein that cuts ...

Researchers developed a CRISPR and single-molecule microarray test that quantifies Candida auris and detects antifungal ...

Aurora Therapeutics has emerged from stealth with $16 million in funding from Menlo Ventures to expand the potential of gene editing to treat rare diseases. Its initial program focuses on ...

If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems to be all about three words ...

Genetic disorders occur due to alterations in the primary genetic material, deoxyribonucleic acid (DNA), of an organism.

Scribe expects to initiate a first-in-human hypercholesterolemia study in mid-2026 with STX-1150, its lead cardiometabolic assetSTX-1150 is designed to deliver durable therapeutic LDL-C lowering with ...